Marsh & McLennan Companies, Inc.
At today's price, Marsh & McLennan Companies, Inc. (MRSH) is priced for +5.0% earnings growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
At $162.37 the market is pricing Marsh & McLennan to grow fee earnings only about 2.8% a year, read off a roughly 21x earnings multiple. That is a modest assumption for a broker that has compounded faster and just posted its 18th straight year of margin expansion. The fundamentals are running ahead of that price. Full-year 2025 delivered 10% revenue growth (4% organic), 9% adjusted EPS growth, and Q1 2026 grew consolidated revenue, adjusted operating income, and EPS each 8%. The fee-financial r
Is MRSH overvalued? See what's priced in →
1,490 institutional managers reported holding MRSH in 13F filings for the quarter ended 2026-03-31. Together they hold about 89% of the company; the top 10 hold 43%. 109 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 7.3M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MRSH has cut its share count 4.7% over the past five years, spending $7.53B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 15 years straight; the current rate is $3.43 a share annually. Cash returned over the past three years: $4.36B in dividends and $4.22B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at MRSH over the trailing three years: 2025: 2 buys totaling $202k. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MRSH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-21 | +2.1% | +2.1% |
| 2023-10-20 | -1.1% | +0.1% |
| 2024-02-13 | +0.5% | -0.1% |
| 2024-04-19 | +2.4% | +6.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MRSH's latest 8-K filings: 2026-06-04 (items 1.01, 1.02, 9.01); 2026-05-22 (items 5.07); 2026-04-16 (items 2.02, 9.01); 2026-04-14 (items 5.02, 9.01); 2026-03-10 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.